Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Candida vulvovaginitis epidemiology and demographics
Introduction
Overview
Overview
Candida vulvovaginitis is not a reportable disease and epidemiological studies on the prevalence of the disease are hard to perform.
Epidemiology and Demographics
Epidemiology and Demographics
- Epidemiological studies on Candida vulvovaginitis are hard to perform, because of several factors:[1][2]
- Candida vulvovaginitis is not a reportable disease.
- The diagnosis of Candida vulvovaginitis is based on clinical presentation and positive laboratory findings. Relying on a positive culture alone would likely overestimate the prevalence of Candida vulvovaginitis.
- The use of over-the-counter (OTC) topical anti-fungals makes it difficult to conduct epidemiological studies.
- Candida is the second most common cause of vaginal infection in young women following bacterial Vaginosis.[3]
Age
- Incidence of Candida vulvovaginitis is higher in pregnant women.[4][5]
- Women in reproductive age group are prone for Candida vulvovaginits and at least one episode is reported in 70 to 75% in this population group.[6]
- 40 to 50% of patients with a prior yeast infection have multiple episodes of yeast infection.[4]
- Among the adult population 5 to 8% women have more than four episodes of infection.[7]
- In 20% asymptomatic healthy adolescent women, Candida species can be isolated from the vagina.[8]
Race
Candida vulvovaginitis is more prevalent among African American women than white American women.[7]
References
References
- ↑ Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, Reed BD, Summers PR (1998). “Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations”. Am. J. Obstet. Gynecol. 178 (2): 203–11. PMID 9500475.
- ↑ Sobel JD (2007). “Vulvovaginal candidosis”. Lancet. 369 (9577): 1961–71. doi:10.1016/S0140-6736(07)60917-9. PMID 17560449.
- ↑ Allsworth JE, Peipert JF (2007). “Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data”. Obstet Gynecol. 109 (1): 114–20. doi:10.1097/01.AOG.0000247627.84791.91. PMID 17197596.
- ↑ 4.0 4.1 Hurley R, De Louvois J (1979). “Candida vaginitis”. Postgrad Med J. 55 (647): 645–7. PMC 2425644. PMID 523355.
- ↑ García Heredia M, García SD, Copolillo EF, Cora Eliseth M, Barata AD, Vay CA; et al. (2006). “[Prevalence of vaginal candidiasis in pregnant women. Identification of yeasts and susceptibility to antifungal agents]”. Rev Argent Microbiol. 38 (1): 9–12. PMID 16784126.
- ↑ Zuckerman, Andrea; Romano, Mary (2016). “Clinical Recommendation: Vulvovaginitis”. Journal of Pediatric and AdolescentGynecology. 29 (6): 673–679. doi:10.1016/j.jpag.2016.08.002. ISSN 1083-3188.
- ↑ 7.0 7.1 Foxman B, Marsh JV, Gillespie B, Sobel JD (1998). “Frequency and response to vaginal symptoms among white and African American women: results of a random digit dialing survey”. J Womens Health. 7 (9): 1167–74. PMID 9861594.
- ↑ Barousse, M M (2004). “Vaginal yeast colonisation, prevalence of vaginitis, and associated local immunity in adolescents”. Sexually Transmitted Infections. 80 (1): 48–53. doi:10.1136/sti.2002.003855. ISSN 1368-4973.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dima Nimri, M.D. [2], Aravind Kuchkuntla, M.B.B.S[3]